Tapentadol conversion reference
Check OpioidCalc's OME factors by route, then open the formulation-specific pharmacology, cautions and supporting sources.
Educational reference for qualified healthcare professionals. Conversion factors estimate oral morphine equivalent daily dose. They are not a recommended switching dose. Confirm the result with a current source and local guidance.
Free download · iOS and Android · Optional Pro features
Current OpioidCalc factors
Multiply the dose or delivery rate in the stated units by the factor to estimate mg oral morphine equivalent per day. These are the factors currently used by OpioidCalc. Methadone uses 4.7 when converting methadone to OME.
| Route | Input units | OME factor |
|---|---|---|
| Oral | mg/day | 0.33 |
Compare a complete regimen in the app
Formulations and cautions
Choose a formulation to read its pharmacology, population, limitations and source references.
OralDefault in appImmediate-release tablet
App source review: 27 August 2026
View details and sources
Immediate-release tablet
App source review: 27 August 2026
View details and sources- Peak concentration or effect
- Approximately 1.25 hours
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Elimination half-life
- Approximately 4 hours
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Bioavailability
- Approximately 32%
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Receptor activity
- Mu-opioid receptor agonism plus norepinephrine reuptake inhibition; exact clinical contributions remain uncertain.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA immediate-release tablet prescribing information12.1 Mechanism of Action. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Metabolism
- Mainly glucuronidation, with minor CYP2C9, CYP2C19 and CYP2D6 pathways.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Active metabolites
- No metabolite contributes to analgesia.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Elimination
- About 99% is eliminated in urine as parent drug or metabolites.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA immediate-release tablet prescribing information12.3 Pharmacokinetics. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Renal impairment
- Parent exposure is similar across renal function, but glucuronide exposure increases.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA immediate-release tablet prescribing information8.7 Renal Impairment. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Hepatic impairment
- Mild and moderate hepatic impairment increase exposure.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA immediate-release tablet prescribing information8.6 Hepatic Impairment. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
OralImmediate-release oral solution
App source review: 27 August 2026
View details and sources
Immediate-release oral solution
App source review: 27 August 2026
View details and sources- Peak concentration or effect
- Approximately 1.25 hours
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Tapentadol hydrochloride oral solution prescribing information12.3 Pharmacokinetics. United States. Source revised 27 July 2026. App review 27 August 2026. Regulatory product information.
- Elimination half-life
- Approximately 4 hours
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Tapentadol hydrochloride oral solution prescribing information12.3 Pharmacokinetics. United States. Source revised 27 July 2026. App review 27 August 2026. Regulatory product information.
- Bioavailability
- Approximately 32%
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Tapentadol hydrochloride oral solution prescribing information12.3 Pharmacokinetics. United States. Source revised 27 July 2026. App review 27 August 2026. Regulatory product information.
- Receptor activity
- Mu-opioid receptor agonism plus norepinephrine reuptake inhibition; exact clinical contributions remain uncertain.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Tapentadol hydrochloride oral solution prescribing information12.1 Mechanism of Action. United States. Source revised 27 July 2026. App review 27 August 2026. Regulatory product information.
- Metabolism
- Mainly glucuronidation, with minor CYP2C9, CYP2C19 and CYP2D6 pathways.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Tapentadol hydrochloride oral solution prescribing information12.3 Pharmacokinetics. United States. Source revised 27 July 2026. App review 27 August 2026. Regulatory product information.
- Active metabolites
- No metabolite contributes to analgesia.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Tapentadol hydrochloride oral solution prescribing information12.3 Pharmacokinetics. United States. Source revised 27 July 2026. App review 27 August 2026. Regulatory product information.
- Elimination
- About 99% is eliminated in urine as parent drug or metabolites.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Tapentadol hydrochloride oral solution prescribing information12.3 Pharmacokinetics. United States. Source revised 27 July 2026. App review 27 August 2026. Regulatory product information.
- Renal impairment
- Parent exposure is similar across renal function, but glucuronide exposure increases.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Tapentadol hydrochloride oral solution prescribing information8.7 Renal Impairment. United States. Source revised 27 July 2026. App review 27 August 2026. Regulatory product information.
- Hepatic impairment
- Mild and moderate hepatic impairment increase exposure.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- Tapentadol hydrochloride oral solution prescribing information8.6 Hepatic Impairment. United States. Source revised 27 July 2026. App review 27 August 2026. Regulatory product information.
OralModified-release tablet
App source review: 27 August 2026
View details and sources
Modified-release tablet
App source review: 27 August 2026
View details and sources- Peak concentration or effect
- 3 to 6 hours
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA ER prescribing information12.3 Pharmacokinetics. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Elimination half-life
- Approximately 5 hours
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA ER prescribing information12.3 Pharmacokinetics. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Steady state
- After the third dose, about 24 hours after starting twice-daily therapy
Population: Adults described in the cited product information
Applicability: United States
- Limitation: This describes the cited twice-daily regimen, not a dosing recommendation.
- NUCYNTA ER prescribing information12.3 Pharmacokinetics. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Bioavailability
- Approximately 32%
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA ER prescribing information12.3 Pharmacokinetics. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Receptor activity
- Mu-opioid receptor agonism plus norepinephrine reuptake inhibition; exact clinical contributions remain uncertain.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA ER prescribing information12.1 Mechanism of Action. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Metabolism
- Mainly glucuronidation, with minor CYP2C9, CYP2C19 and CYP2D6 pathways.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA ER prescribing information12.3 Pharmacokinetics. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Active metabolites
- No metabolite contributes to analgesia.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA ER prescribing information12.3 Pharmacokinetics. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Elimination
- About 99% is eliminated in urine as parent drug or metabolites.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA ER prescribing information12.3 Pharmacokinetics. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Renal impairment
- Parent exposure is similar across renal function, but glucuronide exposure increases.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA ER prescribing information8.7 Renal Impairment. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
- Hepatic impairment
- Mild and moderate hepatic impairment increase exposure.
Population: Adults described in the cited product information
Applicability: United States
- Limitation: Product-specific evidence; do not transfer to other formulations.
- NUCYNTA ER prescribing information8.6 Hepatic Impairment. United States. Source revised 30 December 2025. App review 27 August 2026. Regulatory product information.
Sources used on this page
Other medicine references
Use the full calculator
Compare opioid regimens and inspect formulation-specific information in OpioidCalc for iOS and Android.